IRESSA 250 mg/1
Gefitinib · TABLET, COATED · AstraZeneca Pharmaceuticals LP
No Recall History
Plain English
IRESSA is a tablet, coated containing gefitinib at 250 mg/1, taken oral. Manufactured by AstraZeneca Pharmaceuticals LP.
Key Facts
- Brand Name
- IRESSA
- Generic Name
- Gefitinib
- NDC Code (Product)
0310-0482- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Strength
- 250 mg/1
- Dosage Form
- TABLET, COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA206995
- Drug Class
- Kinase Inhibitor [EPC]
- Marketing Start
- 07/13/2015
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
malignant neoplasm progression1,817 reports
drug resistance1,249 reports
diarrhoea899 reports
death755 reports
rash639 reports
disease progression458 reports
interstitial lung disease419 reports
nausea378 reports
metastases to central nervous system376 reports
dyspnoea330 reports
Frequently Asked Questions
What is IRESSA used for?
IRESSA contains Gefitinib. It is a tablet, coated taken oral. Consult your doctor for specific uses.
Is IRESSA a controlled substance?
IRESSA is not classified as a controlled substance by the DEA.
What is the generic name for IRESSA?
The generic name for IRESSA is Gefitinib. There are 4 other brand versions of Gefitinib.
What is the NDC code for IRESSA 250 mg/1?
The NDC (National Drug Code) for IRESSA 250 mg/1 is 0310-0482, listed by AstraZeneca Pharmaceuticals LP.